Key Stats for Thomson Reuters Stock
- 52-Week Range: $79.7 to $218.5
- Current Price: $88.2
- Street High Target: $210
What Happened?
Thomson Reuters (TRI) hit a 52-week low of $79.70 earlier this year before rebounding to $88.17, but the more important number is 1 million — the active users now on CoCounsel, the company’s AI-powered legal research and drafting assistant that accounts for roughly one-third of total revenue through the Legal Professionals segment.
The February 5 Q4 earnings report confirmed the business underneath the stock-price volatility remains intact: Q4 organic revenue rose 7%, Big 3 segment organic growth — covering Legal, Corporates, and Tax, Audit & Accounting — hit 9%, and adjusted EPS of $1.07 edged past the $1.06 Wall Street consensus.
The operational proof point investors need to hold is the GenAI-enabled share of annualized contract value, a metric that measures how much of Thomson Reuters’ contracted revenue base is attached to AI-powered products — it stood at 15% when first disclosed in Q3 2024 and reached 28% by Q4 2025, a trajectory that peers like RELX and Wolters Kluwer, both rattled by the same AI disruption fears, have not yet matched with equivalent disclosure.
On February 24, Anthropic announced enterprise AI plugins developed alongside partners including Thomson Reuters, and CEO Steve Hasker stated on the Q4 2025 earnings call that “the medium-to-long term winners in legal AI will be those that have trusted content domain expertise and the infrastructure to support verifiable, accountable, professional-grade work,” directly addressing why the company’s 4,500 trained domain experts and centuries of proprietary legal archives constitute a structural barrier rather than a temporary lead.
Thomson Reuters carries roughly $11 billion in capital capacity through 2028, guides for 100 basis points of EBITDA margin expansion annually through that same period, and has a new CFO in Gary Bischoping joining May 8 alongside a next-generation CoCounsel entering beta on April 20 — together making the forward setup more catalyst-rich than the current $88.17 price reflects.
Wall Street’s Take on TRI Stock
The CoCounsel user milestone and the 28% GenAI-enabled ACV share confirm that Thomson Reuters’ AI transition is generating measurable commercial traction, directly supporting TIKR’s estimate of 7.8% revenue growth to $8.1 billion in 2026 and accelerating EPS from $3.92 in 2025 to $4.41, as TIKR estimates.
TIKR estimates project TRI’s EBITDA expanding from $2.9 billion in 2025 to $3.2 billion in 2026, a 10.1% increase reaching a 40.1% margin, supported by the 60%–65% fixed cost base that management confirmed drives operating leverage independent of AI investment cycles.
Thirteen of 17 analysts covering TRI carry a Buy or Outperform rating, with a mean price target of $134.69 against a current price of $88.17, implying 52.8% upside — a consensus stance grounded specifically in the Big 3 organic growth acceleration and the CoCounsel product cycle entering its most active commercial phase.
The analyst target range spans $113.60 on the low end to $210.00 on the high end, with the floor anchored to government contract headwinds already flagged by management and the ceiling contingent on the next-generation CoCounsel general release, set for summer 2026, converting beta traction into full ACV recognition.
What Does the Valuation Model Say?
The TIKR mid-case model assigns a $144.11 price target by December 2030 — a 63.5% total return or 10.9% IRR annually — built on a 6.8% revenue CAGR and net income margins expanding from 23.6% to 25.1%, both of which are anchored to the confirmed $11 billion capital deployment plan and the three-year 100 bps annual EBITDA margin commitment.
Trading at roughly 20x 2026 normalized EPS of $4.41, TRI sits well below its own five-year historical forward P/E average closer to 35x — at equivalent or better earnings growth, with 12.5% EPS growth expected in 2026 alone — making the stock undervalued by any measure that accounts for the business quality underneath the sentiment damage.
The GenAI-enabled share of annualized contract value rising from 15% to 28% in four quarters is the specific operational development that justifies TIKR’s margin expansion assumption, and the $144.11 mid-case target becomes achievable without multiple re-rating if earnings simply compound at the guided rate.
Management’s willingness to pursue buybacks at current levels, confirmed at the Q4 call alongside the new $600 million repurchase program, signals that insiders view the $88 range as a fundamental disconnect, not a fair reflection of the business.
The primary risk is government segment cancellations accelerating beyond the modest headwind already disclosed, which would drag Legal Professionals organic growth below the 8%–9% guided range and pressure the EBITDA margin assumption.
The May 5 Q1 earnings call is the first confirmation event — specifically watch Legal Professionals organic growth ex-government and whether GenAI-enabled ACV continues its sequential march toward 30%, the number that validates the revenue acceleration embedded in TIKR’s 2026 estimate.
Should You Invest in Thomson Reuters Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up TRI stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Thomson Reuters Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze TRI stock on TIKR for Free →
